Spark Therapeutics' Vision Loss Gene Therapy Heads For EU Market
A gene therapy for inherited retinal conditions leading to blindness could be marketed in Europe in 2018, but needs to avoid the setbacks dealt to UniQure’s gene therapy, Glybera, that is being withdrawn from the EU market.
You may also be interested in...
Voretigene neparvovec moves closer to being the first to market a gene therapy in the US with FDA advisory committee review on Oct. 12.
UniQure will not seek marketing authorization renewal for Glybera in the EU before it expires in October, but the company does not see the product's commercial failure as a sign that the market won't accept gene therapies or their high price tags.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.